Visterra Inc:製薬・医療:M&Aディール及び事業提携情報

【英語タイトル】Visterra Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile

GlobalDataが出版した調査資料(DATA904C10588)・商品コード:DATA904C10588
・発行会社(調査会社):GlobalData
・発行日:2018年11月
・ページ数:34
・レポート言語:英語
・レポート形式:PDF
・納品方法:Eメール
・産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明
※お支払金額:換算金額(日本円)+消費税
※納期:即日〜2営業日(3日以上かかる場合は別途表記又はご連絡)
※お支払方法:納品日+5日以内に請求書を発行・郵送(請求書発行日より2ヶ月以内に銀行振込、振込先:三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能)
【レポートの概要】

Summary
Visterra Inc (Visterra), formerly Parasol Therapeutics Inc is a clinical-stage biopharmaceutical company that develops antibody therapies for the treatment of infectious diseases. The company develops precision antibody-based biological medicines for infectious and non-infectious diseases. It concentrates on the prevention and treatment of acute infectious diseases with suboptimal treatment options. Visterra utilizes its hierotope platform to design and engineer antibody-based therapies that target specific regions and epitopes of pathogens. The company’s technology is based on the atomic interaction network analysis that supports in identifying hierotopes. Visterra is headquartered in Cambridge, Massachusetts, the US.

Visterra Inc – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Visterra Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Visterra Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Visterra Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Visterra Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Visterra Inc, Medical Devices Deals, 2012 to YTD 2018 9
Visterra Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Visterra Inc, Pharmaceuticals & Healthcare, Deal Details 12
Venture Financing 12
Visterra Raises Additional USD23.6 Million in Series C Financing 12
Visterra Raises USD30 Million in Series B Venture Financing 14
Visterra Raises US$8.1 Million In Extended Series A Financing 16
Visterra Raises Additional US$13 Million In Series A Financing 18
Partnerships 20
Visterra Enters into Co-Development Agreement with Agency for Science, Technology and Research 20
Visterra and Agency for Science, Technology and Research Enter into Agreement 21
Visterra Enters Into Agreement With Pfizer To Discover Novel Antibodies 22
Licensing Agreements 23
Vir Biotechnology Enters into Licensing Agreement with Visterra 23
Serum Institute of India Enters into Licensing Agreement with Visterra 24
Visterra Enters into Licensing Agreement with MIT for Dengue Virus Antibodies 25
Equity Offering 26
Visterra Withdraws Initial Public Offering of Common Stock for USD53.9 Million 26
Visterra Raises USD23 Million in Private Placement of Series C Preferred Stock 28
Acquisition 29
Otsuka Pharma Acquires Visterra for USD430 Million 29
Visterra Inc – Key Competitors 30
Visterra Inc – Key Employees 31
Visterra Inc – Locations And Subsidiaries 32
Head Office 32
Other Locations & Subsidiaries 32
Recent Developments 33
Product News 33
03/30/2017: Visterra Awarded CARB-X Contract to Advance Development of VIS705 33
Appendix 34
Methodology 34
About GlobalData 34
Contact Us 34
Disclaimer 34

List of Tables
Visterra Inc, Pharmaceuticals & Healthcare, Key Facts 2
Visterra Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Visterra Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Visterra Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Visterra Inc, Deals By Therapy Area, 2012 to YTD 2018 8
Visterra Inc, Medical Devices Deals, 2012 to YTD 2018 9
Visterra Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Visterra Raises Additional USD23.6 Million in Series C Financing 12
Visterra Raises USD30 Million in Series B Venture Financing 14
Visterra Raises US$8.1 Million In Extended Series A Financing 16
Visterra Raises Additional US$13 Million In Series A Financing 18
Visterra Enters into Co-Development Agreement with Agency for Science, Technology and Research 20
Visterra and Agency for Science, Technology and Research Enter into Agreement 21
Visterra Enters Into Agreement With Pfizer To Discover Novel Antibodies 22
Vir Biotechnology Enters into Licensing Agreement with Visterra 23
Serum Institute of India Enters into Licensing Agreement with Visterra 24
Visterra Enters into Licensing Agreement with MIT for Dengue Virus Antibodies 25
Visterra Withdraws Initial Public Offering of Common Stock for USD53.9 Million 26
Visterra Raises USD23 Million in Private Placement of Series C Preferred Stock 28
Otsuka Pharma Acquires Visterra for USD430 Million 29
Visterra Inc, Key Competitors 30
Visterra Inc, Key Employees 31
Visterra Inc, Subsidiaries 32

List of Figures
Visterra Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Visterra Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Visterra Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Visterra Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Visterra Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Visterra Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Visterra Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Visterra Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Visterra Inc, Medical Devices Deals, 2012 to YTD 2018 9

★調査レポート[Visterra Inc:製薬・医療:M&Aディール及び事業提携情報] (コード:DATA904C10588)販売に関する免責事項を必ずご確認ください。
★調査レポート[Visterra Inc:製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆